FNCH News and Press, Finch Therapeutics Group Inc. From 08/25/22

SOMERVILLE, Mass., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel clas...

Seres Therapeutics was founded in 2010 at a time when the Human Microbiome Project was “hot”. So Seres was there when microbiomics began to get serious. Nestle Health Science has been an early investor and concluded a major deal on marketing rights in early 2016. The fir...

Seth Klarman’s 13F portfolio value decreased from $9.30B to $6.77B this quarter. Baupost Group added Warner Bros. Discovery and Amazon while reducing Alphabet, Intel Corp., Nexstar Media, and Verint Systems. The portfolio continues to be heavily concentrated with the top th...

Finch Therapeutics press release ( NASDAQ: FNCH ): Q2 GAAP EPS of -$0.48 misses by $0.07 . Revenue of $0.36M (-87.3% Y/Y). Finch’s cash and cash equivalents as of June 30, 2022 was $104.7 million, compared to $133.5 million as of December 31, 2021. Share...

On track to proceed with enrollment in PRISM4 Phase 3 trial of CP101 in recurrent CDI in H2 2022 On track to submit IND for FIN-211 in children with autism and significant GI symptoms in Q4 2022 Additional results from PRISM-EXT Phase 2 trial of CP101 in recurrent CDI ac...

SER-109 has shown an excellent efficacy and safety profile but is entering a small and crowded market. SER-287 and SER-301 have shown no efficacy. SER-401 did not show efficacy in metastatic melanoma patients. SER-155 has not yet achieved proof of concept but is the most promi...

SOMERVILLE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel clas...

The following slide deck was published by Finch Therapeutics Group, Inc. in conjunction with this event. For further details see: Finch Therapeutics (FNCH) Investor Presentation - Slideshow

SOMERVILLE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel c...

Finch Therapeutics press release (NASDAQ:FNCH): Q1 GAAP EPS of -$0.52. Revenue of $0.35M. Susan Graf appointed board chair and Howard Franklin chief medical officer. Shares +3.59%. For further details see: Finch Therapeutics GAAP EPS of -$0.52, revenue of $0.35M